Drug Type Antibody |
Synonyms BDC 001, BDC001 |
Target |
Action modulators |
Mechanism HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Breast Cancer | Phase 2 | United States | 26 Jul 2024 |






